Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | TNFSF10 | P50591 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSH | P09668 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16182530 | 0.87 | KMT2A (0.41) | KMT2AMEN1TDP1GABBR2CYP1A2 | |
| SCHEMBL21274047 | 0.79 | HASPIN (0.40) | KMT2AMEN1CYP1A2CYP2C19HASPIN | |
| SCHEMBL1254621 | 0.76 | HASPIN (0.42) | KMT2AMEN1HASPINALDH1A1LMNA | |
| SCHEMBL596867 | 0.76 | TDP1 (0.38) | KMT2AMEN1TDP1GFERALDH1A1 | |
| SCHEMBL10916212 | 0.75 | KMT2A (0.46) | KMT2AMEN1TDP1GABBR2CYP1A2 | |
| SCHEMBL1760875 | 0.75 | KMT2A (0.46) | KMT2AMEN1TDP1GABBR2CYP1A2 | |
| SCHEMBL3633581 | 0.75 | MEN1 (0.37) | KMT2AMEN1TDP1GFERALDH1A1 | |
| SCHEMBL11857075 | 0.73 | HASPIN (0.44) | HASPINLMNAMAPK1POLBALPL | |
| SCHEMBL5405499 | 0.72 | KMT2A (0.59) | KMT2AMEN1TDP1GABBR2CYP1A2 | |
| SCHEMBL10680837 | 0.72 | KMT2A (0.45) | KMT2AMEN1TDP1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | Université de Liège (BE) | 2025-06-03 | — | — | US | disclosed |
| CN-113329753-B | Pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, pollution and fouling | 列日大学 | 2024-08-13 | — | — | CN | disclosed |
| EP-3955929-B1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | UNIV LIEGE (BE) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023213198-A1 | USE OF AROMATIC FUSED RING COMPOUND AS TREK-1 ACTIVATOR, AND PHARMACEUTICAL COMPOSITION AND ANALGESIC CONTAINING SAME | 华东师范大学 | 2023-11-09 | — | — | WO | disclosed |
| CN-117003756-A | Use of aromatic condensed-cyclic compounds as TREK-1 activators, pharmaceutical compositions containing same, analgesics | 华东师范大学 | 2023-11-07 | — | — | CN | disclosed |
| CN-111386271-B | Pyrimidine derivatives for the prevention and treatment of bacterial infections | 列日大学 | 2023-05-30 | — | — | CN | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| EP-3752506-B1 | PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS | UNIV LIEGE (BE) | 2022-12-14 | — | — | EP | disclosed |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | Université de Liège (BE) | 2022-09-06 | — | — | US | disclosed |
| EP-3955929-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2022-02-23 | — | — | EP | disclosed |
| US-7253174-B2 | N-heterocyclic inhibitors of TNF-α expression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060276488-A1 | N-heterocyclic inhibitors of TNF-alpha expression | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-07 | — | — | US | disclosed |
| US-20030139435-A1 | N-heterocyclic inhibitors of TNF-alpha expression | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-24 | — | — | US | disclosed |
| EP-0946561-B1 | TRIAZOLO(4,5-D)PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| US-6297232-B1 | TREATMENT OF PLATELET AGGREGATION DISORDERS. | ASTRAZENECA AB (SE) | 2001-10-02 | — | — | US | disclosed |
| EP-0946561-A1 | TRIAZOLO(4,5-D)PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | Astra Pharmaceuticals Limited (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028300-A1 | TRIAZOLO[4,5-D]PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-07-02 | — | — | WO | disclosed |
| US-5397781-A | Pyrimidine derivatives | MOCHIDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-03-14 | — | — | US | disclosed |
| EP-0561175-A1 | Pyrimidine derivatives and pharmaceutical compostions containing them | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-22 | — | — | EP | disclosed |
| US-3975384-A | ANTITHROMBOTICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139435-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, TNFRSF1A | KMT2A 3433/4885MEN1 3985/4885TDP1 2311/4885 |
| US-12318388-B2 | Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling | PIGS, TYMP, TYMS | KMT2A 4361/4885MEN1 4473/4885TDP1 1228/4885 |
| US-20060276488-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, RELA, NFKBIA | KMT2A 3400/4885MEN1 4254/4885TDP1 2715/4885 |
| US-11434241-B2 | Pyrimidine derivatives for prevention and treatment of bacterial infections | TYMP, TYMS, UMPS | KMT2A 4047/4885MEN1 3984/4885TDP1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.